Top

Published in:

01-11-2013 | Meeting Proceedings

Industry progress report on neuro-oncology: Biotech update 2013

Authors: Malte Ottenhausen, Imithri Bodhinayake, Matei Banu, Kartik Kesavabhotla, Ashley Ray, John A. Boockvar

Published in: Journal of Neuro-Oncology | Issue 2/2013

Abstract

For the second time, The Brain Tumor Center of the Weill Cornell Brain and Spine Center, in collaboration with Voices Against Brain Cancer, hosted The Brain Tumor Biotech Summit in New York City in June 2013. After a very successful first summit in 2012, this innovative event has established a platform for intensive networking between neuro-oncologists, neurosurgeons, neuroscientists, members of the biotechnology and pharmaceutical communities, members of the financial community and leaders of non-profit organizations. This year’s summit highlighted dendritic cell vaccines, novel antibody, heat shock protein and targeted therapies as well as exosome technologies, MRI-guided therapies and other novel drug delivery tools. This report presents a short overview of the current progress in brain tumor research and therapy as presented at the 2013 Brain Tumor Biotech Summit.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 PubMedCrossRef

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J clin oncol 27:4733–4740. doi:10.1200/JCO.2008.19.8721 PubMedCrossRef

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J clin oncol 27:740–745. doi:10.1200/JCO.2008.16.3055 PubMedCentralPubMedCrossRef

Health NIo (2013) NIH Fiscal Policy for Grant Awards—FY 2013. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-064.html. Accessed 06 Oct 2013

Haber JS, Banu MA, Ray A, Kesavabhotla K, Boockvar JA (2013) Industry progress report on neuro-oncology: a biotech update. J Neurooncol 112:315–321. doi:10.1007/s11060-012-1036-8 PubMedCrossRef

Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer immunol immunother 62:125–135. doi:10.1007/s00262-012-1319-0 PubMedCentralPubMedCrossRef

Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y, Quillien V (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81:139–148. doi:10.1007/s11060-006-9220-3 PubMedCrossRef

Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR (2007) Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13:566–575. doi:10.1158/1078-0432.CCR-06-1576 PubMedCentralPubMedCrossRef

Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X (2008) Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS ONE 3:e1936. doi:10.1371/journal.pone.0001936 PubMedCentralPubMedCrossRef

10.

Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 36:152–157. doi:10.1097/CJI.0b013e3182811ae4 PubMedCentralPubMedCrossRef

11.

Wheeler CJ, Black KL (2009) DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18:509–519. doi:10.1517/13543780902841951 PubMedCrossRef

12.

See AP, Pradilla G, Yang I, Han S, Parsa AT, Lim M (2011) Heat shock protein-peptide complex in the treatment of glioblastoma. Expert Rev Vaccines 10:721–731. doi:10.1586/erv.11.49 PubMedCrossRef

13.

Binder RJ, Han DK, Srivastava PK (2000) CD91: a receptor for heat shock protein gp96. Nat Immunol 1:151–155. doi:10.1038/77835 PubMedCrossRef

14.

Binder RJ, Srivastava PK (2004) Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 101:6128–6133. doi:10.1073/pnas.0308180101 PubMedCentralPubMedCrossRef

15.

Yang I, Fang S, Parsa AT (2010) Heat shock proteins in glioblastomas. Neurosurg Clin N Am 21:111–123. doi:10.1016/j.nec.2009.09.002 PubMedCrossRef

16.

Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT (2013) Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 19:205–214. doi:10.1158/1078-0432.CCR-11-3358 PubMedCrossRef

17.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465. doi:10.1182/blood-2003-01-0039 PubMedCrossRef

18.

Vaklavas C, Forero-Torres A (2012) Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 3:209–225. doi:10.1177/2040620712443076 PubMedCentralPubMedCrossRef

19.

Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK, Cheng SY (2013) EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. doi:10.1038/onc.2013.198

20.

Estrada-Bernal A, Lawler SE, Nowicki MO, Chaudhury AR, Van Brocklyn JR (2011) The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neurooncol 102:353–366. doi:10.1007/s11060-010-0345-z PubMedCentralPubMedCrossRef

21.

Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476. doi:10.1038/ncb1800 PubMedCentralPubMedCrossRef

22.

Al-Nedawi K, Meehan B, Rak J (2009) Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8:2014–2018PubMedCrossRef

23.

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, ALA-Glioma Study Group (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. doi:10.1016/S1470-2045(06)70665-9 PubMedCrossRef

24.

McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa AR (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110:156–162. doi:10.3171/2008.4.17536 PubMedCrossRef

25.

Chen L, Mu Z, Hachem P, Ma CM, Wallentine A, Pollack A (2010) MR-guided focused ultrasound: enhancement of intratumoral uptake of [(3)H]-docetaxel in vivo. Phys Med Biol 55:7399–7410. doi:10.1088/0031-9155/55/24/001 PubMedCrossRef

26.

Chen X, Cvetkovic D, Ma CM, Chen L (2012) Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance. Med Phys 39:2780–2786. doi:10.1118/1.4705346 PubMedCrossRef

27.

Cohen ZR, Zaubermann J, Harnof S, Mardor Y, Nass D, Zadicario E, Hananel A, Castel D, Faibel M, Ram Z (2007) Magnetic resonance imaging-guided focused ultrasound for thermal ablation in the brain: a feasibility study in a swine model. Neurosurgery 60:593–600; discussion 600. doi:10.1227/01.NEU.0000245606.99946.C6

28.

Desai SB, Patil AA, Nikam R, Desai AS, Bachhav V (2012) Magnetic resonance-guided focused ultrasound treatment for uterine fibroids: first study in Indian women. J Clin Imaging Sci 2:74. doi:10.4103/2156-7514.104307 PubMedCentralPubMedCrossRef

29.

Dobrotwir A, Pun E (2012) Clinical 24 month experience of the first MRgFUS unit for treatment of uterine fibroids in Australia. J Med Imaging Radiat Oncol 56:409–416. doi:10.1111/j.1754-9485.2012.02376.x PubMedCrossRef

30.

Funaki K, Fukunishi H, Sawada K (2009) Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month follow-up. Ultrasound Obstet Gynecol 34:584–589. doi:10.1002/uog.7455 PubMedCrossRef

31.

Marret H, Bleuzen A, Guerin A, Lauvin-Gaillard MA, Herbreteau D, Patat F, Tranquart F (2011) French first results using magnetic resonance-guided focused ultrasound for myoma treatment. Gynecol Obstet Fertil 39:12–20. doi:10.1016/j.gyobfe.2010.08.038 PubMedCrossRef

32.

Monteith SJ, Medel R, Kassell NF, Wintermark M, Eames M, Snell J, Zadicario E, Grinfeld J, Sheehan JP, Elias WJ (2013) Transcranial magnetic resonance-guided focused ultrasound surgery for trigeminal neuralgia: a cadaveric and laboratory feasibility study. J Neurosurg 118:319–328. doi:10.3171/2012.10.JNS12186 PubMedCrossRef

33.

Trumm CG, Stahl R, Clevert DA, Herzog P, Mindjuk I, Kornprobst S, Schwarz C, Hoffmann RT, Reiser MF, Matzko M (2013) Magnetic resonance imaging-guided focused ultrasound treatment of symptomatic uterine fibroids: impact of technology advancement on ablation volumes in 115 patients. Invest Radiol 48:359–365. doi:10.1097/RLI.0b013e3182806904 PubMedCrossRef

34.

Zippel DB, Papa MZ (2005) The use of MR imaging guided focused ultrasound in breast cancer patients; a preliminary phase one study and review. Breast cancer 12:32–38PubMedCrossRef

35.

Larson PS, Starr PA, Bates G, Tansey L, Richardson RM, Martin AJ (2012) An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy. Neurosurgery 70:95–103; discussion 103. doi:10.1227/NEU.0b013e31822f4a91

36.

Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, Lin A, Burrascano C, Ibanez C, Kasahara N, Gruber HE, Jolly DJ (2012) Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 20:1689–1698. doi:10.1038/mt.2012.83 PubMedCentralPubMedCrossRef

37.

Popov M, Linder C, Deckelbaum RJ, Grinberg S, Hansen IH, Shaubi E, Waner T, Heldman E (2010) Cationic vesicles from novel bolaamphiphilic compounds. J Liposome Res 20:147–159. doi:10.3109/08982100903218900 PubMedCrossRef

38.

Dakwar GR, Abu Hammad I, Popov M, Linder C, Grinberg S, Heldman E, Stepensky D (2012) Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. J Control Release 160:315–321. doi:10.1016/j.jconrel.2011.12.042 PubMedCrossRef

39.

Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS (2006) The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 107:2330–2338. doi:10.1182/blood-2005-04-1655 PubMedCentralPubMedCrossRef

40.

Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS (2010) Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol 176:2029–2038. doi:10.2353/ajpath.2010.090755 PubMedCentralPubMedCrossRef

Title: Industry progress report on neuro-oncology: Biotech update 2013
Authors: Malte Ottenhausen
Imithri Bodhinayake
Matei Banu
Kartik Kesavabhotla
Ashley Ray
John A. Boockvar
Publication date: 01-11-2013
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1222-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Industry progress report on neuro-oncology: Biotech update 2013

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

MR-based hypoxia measures in human glioma

The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells

MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis

Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy

Relapse patterns in pediatric embryonal central nervous system tumors

MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas